MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received marketing approval from the National Medical Products Administration (NMPA) for La Ronda’s AnchorMan left atrial appendage occluder system. This marks the first semi-closed left atrial appendage occluder to be approved in China. The product is also under regulatory review in the European Union.
Earlier this month, CardioFlow Medtech acquired a 51% stake in La Ronda for RMB 141 million (USD 20 million). The AnchorMan system comprises a left atrial appendage occluder and a delivery system, designed for non-valvular atrial fibrillation patients with a CHA2DS2-VASC score of 2 or higher, indicating a significant risk of stroke. These patients may have contraindications to long-term oral anticoagulation therapy or may still be at risk of stroke even after undergoing anticoagulation treatment.- Flcube.com
